{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["18(6)"],"submitter":["Loi S"],"funding":["Pfizer Inc"],"pubmed_abstract":["<h4>Aim</h4>Palbociclib was approved in the United States in 2015 to treat estrogen receptor-positive/human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC). This study evaluated outcomes and safety in patients treated with palbociclib in Australia and India with hormone receptor-positive (HR+)/HER2- ABC before palbociclib became commercially available.<h4>Methods</h4>Postmenopausal women (≥18 years) with HR+/HER2- ABC who were appropriate candidates for letrozole therapy received palbociclib 125 mg once daily for 21 days followed by 7 days off, and letrozole 2.5 mg once daily (continuous). Safety, tumor response, and patient-reported outcomes (Australian cohort) were evaluated.<h4>Results</h4>In total, 252 patients received palbociclib plus letrozole (Austr"],"journal":["Asia-Pacific journal of clinical oncology"],"pagination":["560-569"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9787838"],"repository":["biostudies-literature"],"pubmed_title":["Palbociclib plus letrozole as treatment for postmenopausal women with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer for whom letrozole therapy is deemed appropriate: An expanded access study in Australia and India."],"pmcid":["PMC9787838"],"pubmed_authors":["McCarthy N","Lu DR","White M","Gore V","Redfern A","Boyle F","Doval DC","Alam M","Kim S","Karapetis CS","Khasraw M","Oakman C","Loi S","Binko J"],"additional_accession":[]},"is_claimable":false,"name":"Palbociclib plus letrozole as treatment for postmenopausal women with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer for whom letrozole therapy is deemed appropriate: An expanded access study in Australia and India.","description":"<h4>Aim</h4>Palbociclib was approved in the United States in 2015 to treat estrogen receptor-positive/human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC). This study evaluated outcomes and safety in patients treated with palbociclib in Australia and India with hormone receptor-positive (HR+)/HER2- ABC before palbociclib became commercially available.<h4>Methods</h4>Postmenopausal women (≥18 years) with HR+/HER2- ABC who were appropriate candidates for letrozole therapy received palbociclib 125 mg once daily for 21 days followed by 7 days off, and letrozole 2.5 mg once daily (continuous). Safety, tumor response, and patient-reported outcomes (Australian cohort) were evaluated.<h4>Results</h4>In total, 252 patients received palbociclib plus letrozole (Austr","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Dec","modification":"2026-05-31T02:16:59.069Z","creation":"2025-04-04T21:00:30.01Z"},"accession":"S-EPMC9787838","cross_references":{"pubmed":["34908235"],"doi":["10.1111/ajco.13653"]}}